217 Queen Street West
Suite 301
Toronto, ON M5V 0R2
Canada
https://awaknlifesciences.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 6
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. George Scorsis | Co-founder & Chairman of the Board | S.O. | S.O. | 1977 |
Mr. Anthony Tennyson | Co-founder, President, CEO & Director | 240k | S.O. | S.O. |
Mr. Jonathan James Held C.A., CPA, CA | Co-founder, CFO, Chief Business Officer & Secretary | 150k | S.O. | 1986 |
Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer | S.O. | S.O. | S.O. |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary Sketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
L’ISS Governance QualityScore de AwaknLifeSc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..